Navigation Links
McCormick Foundation Invests $5 Million in Chicago Initiatives Addressing Civic Health and Education
Date:1/9/2009

CHICAGO, Jan. 9 /PRNewswire/ -- At its December meeting, the Board of Directors of the McCormick Foundation approved grants to 13 nonprofit agencies. These fourth quarter grants support the Foundation's focus on its hometown and on encouraging citizens to become more active, informed and engaged. The Foundation, part of the legacy of former Chicago Tribune publisher Robert R. McCormick, has a long history of leadership in citizenship, journalism and early childhood education issues, both locally and nationally. These most recent grants are targeted directly at Chicago-area needs and reflect McCormick's ties to the city and its people. A complete listing of these fourth-quarter grants is provided below.

"Although Robert R. McCormick was a true citizen of the world, his heart, and his major contributions, were always in Chicago," said David L. Grange, president and chief executive officer, McCormick Foundation, "The McCormick Foundation is part of his legacy and, like McCormick, the Foundation seeks to improve civic health. We are proud to help fund these important initiatives and to be part of efforts to support our city, our communities, and our citizens."

2009 Program Grant Highlights

To ensure a national treasure remains relevant for generations to come, the McCormick Foundation granted $3 million to the Museum of Science and Industry (MSI) (http://www.msichicago.org) for the U-505 (http://www.msichicago.org/whats-here/exhibits/u-505) exhibit. The U-505 is the only maritime vessel of its kind on display in the United States. The multi-year grant is part of "Science Rediscovered," a comprehensive campaign focused on updating and developing new exhibits for children that stimulate interest and learning. The grant allows MSI to establish a fund for the U-505
'/>"/>

SOURCE McCormick Foundation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. ev3 Inc. Appoints Shawn McCormick as New Sr. Vice President and Chief Financial Officer
2. Easter Seals Awarded $100,000 McCormick Foundation Grant to Help Employ Wounded Veterans
3. Weight Watchers Names Steven C. McCormick as President, North America
4. McCormick, MD, Named to AMA Council
5. Louise McCormick Joins Heskas Board of Directors
6. Adult-Care.Org, After Its Initial Launch on August 28, 2007, in October 2007 Captures Attention of One of the Fastest Growing NASDAQ Companies, McCormick & Schmicks Seafood Restaurants in Marketing Partnership
7. Blackbaud to Deliver National CRM Database and Bilingual Website for The Kidney Foundation of Canada
8. Jeff Timmons and the Heather Trew Foundation Join Forces to Promote Organ Donations
9. Global Action for Children Announces Half Million Dollar Grant From the Bill & Melinda Gates Foundation
10. Kentucky Medical Services Foundation Completes Successful Charge Capture Technology Conversion
11. Sheffield Teaching Hospitals NHS Foundation Trust delivers same day patient discharge via BigHand Digital Dictation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/4/2009)...results, study says , , FRIDAY, July 3...ates scored better than their counterparts in Engl...se of differences in levels of depression and educ...re aggressive treatment for heart disease, a new s...d delayed recall of 10 common nouns, such as tree,...
(Date:7/3/2009)...e to breaking news of drugs reportedly found at th...ociety of Anesthesiologists releases the following...esiologists (ASA), which is made up of , physicia...t know the specific circumstances surrounding Mich...y maintains that Diprivan, or its generic name Pro...
(Date:7/3/2009)...ish knows what it,s like being addicted to prescri...America,s "Other" Drug Problem Prescription Medica... his story of addiction and recovery and how he go...m Center drug and alcohol rehabilitation program...m/09-0703-NarcononMI_72dpi.jpg ) , *(Photo Capti...
(Date:7/3/2009)...iddle age may triple the risk, study shows , ...-aged adults who live alone are twice as likely to...life compared to those who are married or live wit...ong those who are divorced or widowed, according t..., The study included 2,000 men and women in Fin...
Breaking Medicine News(10 mins):Health News:On Memory, Older Americans Outsmart the English 2Health News:American Society of Anesthesiologists Releases Following Statement Related to Media Inquires Regarding Michael Jackson's Death 2Health News:Narconon Graduate Successfully Recovers From Prescription Drug Abuse 2Health News:Living Alone Increases Odds of Developing Dementia 2
...of clot formation inside a coronary stent is three...days, the majority of angioplasties involve placem...oronary artery to keep it open. But the very act o...sel walls and may promote formation of a clot - ir...
...cal industries, Ranbaxy Laboratories and Cipla ann...ay formulation of Ciprofloxacin. The formulation h...dia’s (DCGIs) approval for marketing in India. Cip...pectrum antibiotic. The domestic market for ciprof...
...he liver from damage, according to new research fr...its to laboratory rats. The rats were then given D...ge by interfering with cell synthesis and results ...o obtained the least amount of liver damage.// The...
... adverse effects on the heart among the young and ...s, which have a diameter of less than ten micromet...function, by entering the circulation, especially ...According to a new study by researchers at Harvard...
Other Medicine News:
(Date:6/29/2009)... patients achieved primary and secondary endpoints... -- AcelRx Pharmaceuticals, Inc. today announced p...tudy evaluating the safety and efficacy of its ARX...acute post-operative pain in patients requiring op... placebo, patients receiving ARX-01 Sufentanil Nan...
(Date:6/28/2009)...O, June 29 , - Study Trigge...sei Group Corporation ("Sosei"; TSE Mothers Index:...) announce the commencement of a Phase III,clinic...ong-acting muscarinic,antagonist (LAMA) for the t...,(COPD). NVA237 is a dry powder formulation for or...
(Date:6/26/2009)...oval of New Anti-TNF Therapy in Three Rheumatic Di..., HORSHAM, Pa. and KENILWORTH, N.J., June 26 /PRNe...nd Schering-Plough Corporation (NYSE: SGP ) anno...cts for Human Use (CHMP) of the European Medicines...ding the approval of SIMPONI(TM) (golimumab) as a ...
(Date:6/25/2009)...ighlighted at the College on Problems of Drug Depe... King Pharmaceuticals, Inc. (NYSE:...ting safety and efficacy data for ACUROX(R) and ...rmulations that are in development, at the 71st An...pendence. King is also developing other pain medi...
Breaking Medicine Technology:AcelRx Announces Positive Phase 2 Results from a Study of ARX-01 Sufentanil NanoTabs in Treating Post-Operative Pain 2AcelRx Announces Positive Phase 2 Results from a Study of ARX-01 Sufentanil NanoTabs in Treating Post-Operative Pain 3AcelRx Announces Positive Phase 2 Results from a Study of ARX-01 Sufentanil NanoTabs in Treating Post-Operative Pain 4Sosei and Vectura Announce Start of Phase III Clinical Study With NVA237 2Sosei and Vectura Announce Start of Phase III Clinical Study With NVA237 3Sosei and Vectura Announce Start of Phase III Clinical Study With NVA237 4SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 2SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 3SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 4SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 5SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 6SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 7SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 8SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 9SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 10King Pharmaceuticals Showcases Data From Pain Pipeline of Medicines Designed to Deter Common Methods of Non-Therapeutic Use 2King Pharmaceuticals Showcases Data From Pain Pipeline of Medicines Designed to Deter Common Methods of Non-Therapeutic Use 3King Pharmaceuticals Showcases Data From Pain Pipeline of Medicines Designed to Deter Common Methods of Non-Therapeutic Use 4King Pharmaceuticals Showcases Data From Pain Pipeline of Medicines Designed to Deter Common Methods of Non-Therapeutic Use 5King Pharmaceuticals Showcases Data From Pain Pipeline of Medicines Designed to Deter Common Methods of Non-Therapeutic Use 6Lincare Holdings Inc Announces Fourth Quarter and Year Ended 2008 Financial Results 36155 1Lincare Holdings Inc Announces Fourth Quarter and Year Ended 2008 Financial Results 36155 2Lincare Holdings Inc Announces Fourth Quarter and Year Ended 2008 Financial Results 36155 3Lincare Holdings Inc Announces Fourth Quarter and Year Ended 2008 Financial Results 36155 4Lincare Holdings Inc Announces Fourth Quarter and Year Ended 2008 Financial Results 36155 5Lincare Holdings Inc Announces Fourth Quarter and Year Ended 2008 Financial Results 36155 6Lincare Holdings Inc Announces Fourth Quarter and Year Ended 2008 Financial Results 36155 7Lincare Holdings Inc Announces Fourth Quarter and Year Ended 2008 Financial Results 36155 8Emergency Nurses Association Announces Corporate Sponsors for Leadership Conference 36153 1Emergency Nurses Association Announces Corporate Sponsors for Leadership Conference 36153 2Pharmasset Reports Fiscal First Quarter 2009 Financial Results 10370 1Pharmasset Reports Fiscal First Quarter 2009 Financial Results 10370 2Pharmasset Reports Fiscal First Quarter 2009 Financial Results 10370 3Pharmasset Reports Fiscal First Quarter 2009 Financial Results 10370 4Pharmasset Reports Fiscal First Quarter 2009 Financial Results 10370 5Pharmasset Reports Fiscal First Quarter 2009 Financial Results 10370 6Pharmasset Reports Fiscal First Quarter 2009 Financial Results 10370 7Pharmasset Reports Fiscal First Quarter 2009 Financial Results 10370 8Taking Statins Faithfully Lengthens Life 36144 1Taking Statins Faithfully Lengthens Life 36144 2
....--(BUSINESS WIRE)--Jun 21, 2007 - BioSante,Pharma...on the,Women,s Health Initiative (WHI) Coronary Ar...England Journal of Medicine (NEJM).,The study foun...eceived a standard dose of estrogen therapy had si...the end of the study period,compared with those ta...
... 21, 2007-Novo Nordisk today announced clinical,re...liraglutide -,the once-daily human GLP-1 analogue....utide Effect and Action in Diabetes) programme,and...uately,controlled by two of the most widely used o...ea (glimepiride). All patients in the,study contin...
Other Medicine Technology:New Analysis of WHI Data Shows Reduced Levels of Coronary Artery,Calcification, a Predictor of Cardiovascular Events, in Women aged,50-59 taking Estrogen Therapy 2New Analysis of WHI Data Shows Reduced Levels of Coronary Artery,Calcification, a Predictor of Cardiovascular Events, in Women aged,50-59 taking Estrogen Therapy 3New Analysis of WHI Data Shows Reduced Levels of Coronary Artery,Calcification, a Predictor of Cardiovascular Events, in Women aged,50-59 taking Estrogen Therapy 4Liraglutide provides significantly better glucose control than,insulin glargine in phase 3 study 2Liraglutide provides significantly better glucose control than,insulin glargine in phase 3 study 3Liraglutide provides significantly better glucose control than,insulin glargine in phase 3 study 4
Surgitie&trade Single Use Ligating Loops with Delivery System
Surgitie&trade Single Use Ligating Loops with Delivery System
Surgitie&trade Single Use Ligating Loops with Delivery System
ENDO STITCH&trade Triple-Stitch Single Use Loading Units for use with ENDO Stitch* 10 mm Suturing Device.
Medicine Products: